Abstract | OBJECTIVE: The aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary therapy in treating Crohn's Disease (CD) in conjunction with Remicade. DESIGN: Systematic searches were performed by three researchers using electronic databases (ProQuest Medical Library, CINAHL Complete, and PUBMED) to locate and identify articles to meet a predetermined set of inclusion criteria. Specifically full text, peer-reviewed articles published after 2007 were included if they studied human participants 18 years or older. RESULTS: CONCLUSIONS: LOR of Remicade occurs when IL-1 increases, and it can cause malignancy. Research shows Curcumin reduces IL-1 and improves cancer outcomes. Future research, using both Remicade and Curcumin, would have to be done, but preliminary data would suggest using both would reduce LOR. Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers.
|
Authors | Allaire Schneider, Ivy Hossain, Julia VanderMolen, Kara Nicol |
Journal | Complementary therapies in medicine
(Complement Ther Med)
Vol. 33
Pg. 32-38
(Aug 2017)
ISSN: 1873-6963 [Electronic] Scotland |
PMID | 28735823
(Publication Type: Journal Article, Review, Systematic Review)
|
Copyright | Copyright © 2017 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Interleukin-1
- Plant Extracts
- Tumor Necrosis Factor-alpha
- Infliximab
- Curcumin
|
Topics |
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Colorectal Neoplasms
(blood, etiology, prevention & control)
- Crohn Disease
(blood, complications, drug therapy)
- Curcuma
(chemistry)
- Curcumin
(pharmacology, therapeutic use)
- Humans
- Infliximab
(pharmacology, therapeutic use)
- Interleukin-1
(blood)
- Phytotherapy
- Plant Extracts
(pharmacology, therapeutic use)
- Tumor Necrosis Factor-alpha
(blood)
|